Subspecialty	Nephrology
Clinical Interests	Kidney Disorders
	Hypertension
	Nephrology
Languages	English
Gender	Male
E-mail	mike.lipkowitz@mssm.edu
Education and Training	MD, S.U.N.Y., Downstate Medical Center
	Residency, Internal Medicine, Carney Hospital
	Residency, Internal Medicine, Carney Hospital
	Fellowship, Nephrology, Mount Sinai Hospital

Curriculum Vitae: http://www.mountsinai.org/supporting-files/cv/lipk...

Education and Training	MD, S.U.N.Y., Downstate Medical Center
	Residency, Internal Medicine, Carney Hospital
	Residency, Internal Medicine, Carney Hospital
	Fellowship, Nephrology, Mount Sinai Hospital
Board Certification	Nephrology

Subspecialty	Nephrology
Clinical Interests	Kidney Disorders
	Hypertension
	Nephrology
Languages	English
Board Certification	Nephrology

The Genetics and Pharmacogenetics of Hypertension and Kidney Disease
There appear to be genetic predispositions for hypertension and renal disease. To better understand this, we are evaluating a large multicenter clinical data set, the African American Study of Kidney Disease and Hypertension (AASK). Genetic and pharmacogenomic studies of AASK subjects are ongoing to try to understand the genetic basis for susceptibility to hypertension, progressive renal failure, and their sequelae such as cardiac hypertrophy, coronary artery disease, and atherosclerosis, as well as effectiveness of drug therapy.

The Human Uric Acid Transporter hUAT
Recent data suggest that elevated uric acid levels may cause hypertension, renal disease and cardiovascular disease in addition to gout. The mechanisms by which uric acid levels become elevated are poorly understood. We are studying the molecular mechanisms of urate transport, particularly the urate ion channel hUAT, and its role in hyperuricemia in AASK subjects and in subjects with severe gout.

Proteomic predictors of renal disease progression
Recent clinical proteomic studies in cancer subjects have shown that patterns of serum proteins can be strong predictors of normal or disease states. We are performing a proteomics project to determine whether patterns of serum proteins can predict progression and non-progression of renal disease in AASK subjects.

Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown J, A. CYP4A11 Variant Associated with Blood Pressure in African American Men. JASN 2008 Apr 2; Epub ahead of print.

Appel LJ, Wright JT, Greene T, Kusek JW, Lewis J, Wang X, Norris K, Bakris G, Rahman M, Contreras G, Lipkowitz MS, Rostand SG, Kopple J, Gabbai F, Shulman G, Gassman J, Charleston J, Agodoa LY, A. The Long-term Effects of Renin-Angiotensin System Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African-Americans. Archives of Internal Medicine 2008; 168: 832-839.

Ito K, Chen J, Khodadadian JJ, Vaughan ED Jr., Lipkowitz M, Poppas DP, Felsen D. Adeno-associated viral vector transduction of Green Fluorescent protein (GFP) in kidney: Effect of unilateral ureteral obstruction. BJU Int 2008 Feb; 101(3): 376-381.

Bhatnagar V, O'Connor DT, Schork N, Salem RM, Nievergelt C, Rana BK, Smith DW, Bakris G, Middleton J, Norris K, Wright J, Cheek D, Hiremath L, Contreras G, Lipkowitz MS, A. Angiotensin converting enzyme (ACE) gene polymoprhisms predict the time-course of blood pressure response to ACE inhibition in the AASK trial. J HTN 2007; 25: 2082-2092.

Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006 Oct; 17(10): 2928-2936.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165(8): 947-953.

Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LG. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005 Sep-Oct; 25(5): 425-433.

Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER 3rd, Ojo A, Sika M, Wilkening B, Toto RD. African American Study of Kidney Disease and Hypertension Study Group Investigators. Blood pressure control, drug therapy, and kidney disease. Hypertension 2005; 46(1): 44-50.

Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 Is The Sugar-Regulated Urate Transporter/Channel UAT. Glycoconjugate Reviews 2004; 19: 491-498.

Lipkowitz MS, Leal-Pinto E, Rappoport JZ, Najfield V, Abramson RG. Functional Reconstitution, Membrane Targeting, Genomic Structure and Chromosomal Localization of a Human Urate Transporter. J Clin Invest 2001; 107: 1103-1115.